GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (OTCPK:ANPCF) » Definitions » Debt-to-EBITDA

ANGLE (ANPCF) Debt-to-EBITDA : -0.24 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ANGLE Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ANGLE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.77 Mil. ANGLE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $5.00 Mil. ANGLE's annualized EBITDA for the quarter that ended in Jun. 2023 was $-24.16 Mil. ANGLE's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ANGLE's Debt-to-EBITDA or its related term are showing as below:

ANPCF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.24   Med: -0.16   Max: -0.11
Current: -0.21

During the past 13 years, the highest Debt-to-EBITDA Ratio of ANGLE was -0.11. The lowest was -0.24. And the median was -0.16.

ANPCF's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.005 vs ANPCF: -0.21

ANGLE Debt-to-EBITDA Historical Data

The historical data trend for ANGLE's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE Debt-to-EBITDA Chart

ANGLE Annual Data
Trend Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.11 -0.15 -0.24

ANGLE Semi-Annual Data
Oct13 Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.15 -0.28 -0.21 -0.24

Competitive Comparison of ANGLE's Debt-to-EBITDA

For the Diagnostics & Research subindustry, ANGLE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANGLE's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ANGLE's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ANGLE's Debt-to-EBITDA falls into.



ANGLE Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ANGLE's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.806 + 5.285) / -25.879
=-0.24

ANGLE's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.774 + 5.001) / -24.164
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


ANGLE  (OTCPK:ANPCF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ANGLE Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ANGLE's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ANGLE (ANPCF) Business Description

Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.

ANGLE (ANPCF) Headlines

From GuruFocus

Angle PLC Announces AACR 2019

By ACCESSWIRE AccessWire 04-12-2019

Angle PLC Announces Holding(s) in Company - (1)

By ACCESSWIRE ACCESSWIRE 07-08-2020

Angle PLC Announces Exercise of Options and Total Voting Rights

By ACCESSWIRE ACCESSWIRE 04-30-2021

Angle PLC Announces Holding(s) in Company - (2)

By ACCESSWIRE ACCESSWIRE 07-08-2020